The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.
Featured Posts
According to the research brief, Enbrel will likely sustain a 60% discount, while Imbruvica will be subject to a minimum discount of 25%. Two other medicines—Pfizer’s Ibrance (palbociclib) and Astellas’ and Pfizer’s Xtandi (enzalutamide)—will also see at least a 25% discount. Taken together, these four drugs could save the federal government $1.8 billion.
One of the world’s largest manufacturers and distributors of medical and surgical products such as needles, syringes and sharps disposal units is the latest company to benefit from an ongoing recovery in demand for non-urgent surgical procedures.
Regeneron and partner Bayer are betting on longer intervals between injections through the higher dose to win over patients.
Moderna expects $6 billion to $8 billion in sales from its COVID shots this year, up from its previous forecast of $5 billion, driven by potential U.S. demand for 50 to 100 million doses in the fall season.
The doctors are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder, according to Reuters interviews with ten prescribers across the country.
Today the company warned of a steeper earnings decline due to a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn.
British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.
The biopharma company reported sales of $2.24 billion in the second quarter for the cystic fibrosis treatment, beating analysts’ estimate, after it won FDA approval in children ages two to five in April.
A downward spiral has continued into 2023, with many good companies laying off employees and shuttering promising clinical programs as they’ve tried to keep the lights on until the dark times are behind us and they again have access to capital. In the midst of such hardships, few companies have chosen to go public.